Seneca Biopharma, a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, has completed its new cell manufacturing facility in Suzhou, China. The facility will be used to manufacture NSI-566, the company's lead stem cell therapy, for clinical trials within China, including a non-GCP compliant Phase II trial currently underway for the treatment of chronic ischemic stroke at the BaYi Brain Hospital in Beijing. Stroke is the leading cause of death and disability in China.
 
"Completion of our new facility in Suzhou is a key milestone in Seneca's product development strategy," said Ken Carter, executive chairman, Seneca. "This facility will allow us to manufacture cells to support our current and future clinical trials in China. I'd like to personally thank the staff who have been able to move forward on this plan while maintaining their safety during these uncertain times."